Urogen Pharma vs Valneva
Valneva is the larger business, with $197m of revenue in fiscal 2025 against $110m for Urogen Pharma (1.8 times as much). Urogen Pharma grew faster (21.4% against 7.6%). Valneva kept more of each dollar of sales as profit: a net margin of -66.0% against -139.8%.
| Latest fiscal year | Urogen PharmaURGN, 2025 | ValnevaVALN, 2025 |
|---|---|---|
| Revenue | $110m | $197m |
| Revenue growth | 21.4% | 7.6% |
| Net income | −$153m | −$130m |
| Operating margin | -113.7% | -47.0% |
| Net margin | -139.8% | -66.0% |
| Return on equity | — | -83.4% |
| Free cash flow | −$163m | −$64.8m |
| Cash | $111m | $129m |
| Total debt | $125m | $210m |
| Debt to equity | — | 168.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 291 | — |
| Market value | $1.68bn | $476m |
| Price vs our value range | — | — |
| Moat score | 25 (Weak) | — |
| Insider trades, 12 months | 0 buys, 15 sales | 0 buys, 0 sales |